The Global Coagulation Analyzers Market, By Product Type (Analyzers (Clinical Laboratory Analyzers, Point of Care Analyzers) and Consumables (Reagents & Kits, Point-of-care strips), By Test Type (Activated Partial Thromboplastin Time Test, Prothrombin Time Test, D-Dimer Test, Fibrinogen Test, and Other Coagulation Tests), and By End User (Hospitals, Diagnostic Laboratories, Research Institutes, and Others) was valued at US$ 2,481.78 million in 2017 and is projected to exhibit a CAGR of 9.7% over the forecast period (2017–2025).
Coagulation analyzers are used in diagnosis of bleeding disorders and thrombotic cases. The presence of coagulation analyzers these days are fully automated infuse with several advanced features to perform various functions such as cap piercing, primary tube sampling, dilution and automatic rerun. This ultimately, lowers total cost, improves the quality of patient care and assures regulatory compliance in the clinical laboratory. Instrumentation Laboratory — a Werfen company’s product — ACL TOP Family 50 series is designed for mid- to high-volume clinical laboratories, which offers the most advanced automation and quality management, for routine to specialty assays, including clotting, chromogenic, and immunological assays. These devices are highly sensitivity and offers accurate information and results thus, boosting the market growth of the coagulation analyzers over the forecast period.
Browse 22 Market Data Tables and 28 Figures spread through 150 Pages and in-depth TOC on "Coagulation Analyzers Market, by Product Type (Analyzers (Clinical Laboratory Analyzers, Point of Care Analyzers) and Consumables (Reagents & Kits, Point-of-care strips), by Test Type (Activated Partial Thromboplastin Time Test, Prothrombin Time Test, D-Dimer Test, Fibrinogen Test and Other Coagulation Tests) and by End User (Hospitals, Diagnostic Laboratories, Research Institutes and Others) - Global Forecast to 2025"
To know the latest trends and insights related to coagulation analyzers market, click the link below:
Companies are focusing on developing next generation diagnostic analyzers to help to improve specificity, accuracy, and overall productivity without making the test expensive. They are developing portable and small sized analyzers, in order to enhance their market share. These innovative analyzers offer the same results in less turnaround time making them hassle free and feasible for the operators. For instance, in July 2017, Sysmex America, Inc. launched its XN-L automated hematology analyzers in the U.S. to meet the demand of lower-volume hematology analyzers. Moreover, in 2014, Siemens Healthineer’s product Xprecia Stride Coagulation Analyzer — a handheld device — received U.S. FDA approval for reliable monitoring of oral anticoagulation therapy with warfarin, a vitamin K antagonist. Moreover, in 2015, this same analyzer, received the Red Dot award for its design quality. The Red Dot Award is the largest and most recognized international product competition in the world for product design quality. These factors are expected to augment growth of the coagulation analyzers market over the forecast period. Key players in the market are also engaged in strategic acquisitions and collaborations to increase their product portfolios and to introduce new platform technologies. For instance, in January 2012, Roche entered into a strategic alliance with Technoclone — a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria — to further expand the company’s reagent portfolio in coagulation diagnostics. This in turn, will help the Roche to retain the market share in in-vitro diagnostics. Furthermore, in August 2015, Abbott Laboratories entered into a definitive agreement to acquire Omnilab — a middleware provider for clinical diagnostics and blood transfusion laboratories — to expand lab offerings to international markets outside the U.S.
Key Takeaways of the Coagulation Analyzers Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.